News Sentiment

BMRN sentiment intelligence

Biomarin Pharmaceutical Inc news scored across direct company coverage, industry context, sector read-through, source quality, and freshness.

Chart Weekly report Factors RSS feed
Weighted score 57 Balanced news tone 63 relevant articles
Exchange NASDAQ United States
Sector Healthcare Market context
Industry Biotechnology Read-through group
Latest close 59.59 Week of 17 Jul 2026
Weighted tone 57/100

Balanced news tone

Market reaction Balanced read

News tone and price action are not far from neutral.

Primary event Market update

73/100 classification confidence.

Company focus 54

directly relevant articles

Source quality 0

high-authority source matches

Trend context Trend inactive

+0.8% over one week, +9.0% over four weeks, trend inactive, and near fair-value range.

Latest direct headline Neutral

Biomarin Pharmaceutical Inc. (BMRN) Q3 2024 Earnings Report - Results, Call & Slides

Market Reaction

Balanced read

54/100 confidence

News tone and price action are not far from neutral.

Primary event Market update 73/100 classification
One-week reaction 0.8% Price digesting
Trend fit Trend inactive 9.0% over four weeks
Fair value -15.3% Near fair-value range

Sentiment Mix

Positive, neutral, negative

Weighted by relevance
Positive 22
Neutral 36
Negative 5

Relevance

Why the article matched

Direct first
Direct company coverage 54
Industry context 9
Sector context 0

Sources

Coverage mix

Publishers
Market source 13
TradingView 9
simplywall.st 7
PR Newswire 5
Stock Titan 3
ChartMill 3
Ad-hoc-news.de 2
Stock Traders Daily 2

Event Lens

What the news is about

Classified themes
Earnings 22
Market update 22
Analyst action 8
Deals and strategy 3
Regulatory and legal 3
Guidance 3
Balance sheet 2

Sentiment Trail

Score over time

50 baseline
Above 50 Neutral zone Below 50

News Tape

Relevant headlines

Showing 31-60 of 63
TradingView Direct company coverage

Enterprise value to revenue forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN

This article focuses on the enterprise value to revenue forward metric for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It appears to be a stub or a section of a larger financial analysis provided by TradingView, indicating a specific financial valuation ratio for the company.

Tone
Neutral 50/100
Event
Earnings
Published
26 Jun 2026 10:13
Source
TradingView
TradingView Direct company coverage

Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh

This page provides an overview of Biomarin Pharmaceutical Inc. Shs Unsponsored Brazilian Depositary Receipt Repr 0.5 Sh (BMFBOVESPA:B1MR34) on TradingView. It offers access to actuals and estimates for financial data, including income statements, balance sheets, cash flow, and va

Tone
Neutral 50/100
Event
Balance sheet
Published
26 Jun 2026 06:11
Source
TradingView
TradingView Direct company coverage

BioMarin Pharmaceutical Inc. Actuals & Estimates (NASDAQ:BMRN)

This article provides an overview of BioMarin Pharmaceutical Inc. (NASDAQ:BMRN) stock, including its current price, historical performance, and analyst forecasts. It details financial actuals and estimates for revenue, earnings per share, net income, and EBITDA, and states the co

Tone
Positive 70/100
Event
Earnings
Published
25 Jun 2026 19:10
Source
TradingView
TradingView Direct company coverage

Price to sales forward of BioMarin Pharmaceutical Inc. – NASDAQ:BMRN

This article displays the forward price-to-sales ratio for BioMarin Pharmaceutical Inc. (NASDAQ: BMRN). It presents a specific financial metric for the company as listed on the Nasdaq Stock Market. The content is sparse, mainly serving as a data point within a larger financial in

Tone
Neutral 50/100
Event
Market update
Published
25 Jun 2026 16:41
Source
TradingView
Stock Traders Daily Direct company coverage

How Biomarin Pharmaceutical Inc. (BMRN) Affects Rotational Strategy Timing

Quantitative analysis suggests that Biomarin Pharmaceutical Inc. (BMRN) is exhibiting a mid-channel oscillation pattern, with strong near-term sentiment but a neutral mid and long-term outlook. The report identifies an exceptional 28.2:1 risk-reward setup targeting an 8.1% gain v

Tone
Positive 64/100
Event
Guidance
Published
25 Jun 2026 04:24
Source
Stock Traders Daily
Market source Direct company coverage

BioMarin (BMRN) Presents Positive Phase 2 Data for VOXZOGO in Hypochondroplasia Treatment

BioMarin (BMRN) presented positive Phase 2 extension study data for VOXZOGO (vosoritide) in children with hypochondroplasia, showing sustained improvements in growth parameters over three years. The company plans to submit a supplemental NDA to the FDA in Q3 2026. Additionally, B

Tone
Positive 86/100
Event
Market update
Published
23 Jun 2026 19:55
Source
Market source
Insider Monkey Direct company coverage

10 Most Promising Stocks with Highest Upside Potential

This article highlights BioMarin Pharmaceutical Inc. (NASDAQ: BMRN) as one of the most promising stocks with high upside potential, noting its average upside potential of 55.42%. The company recently presented positive clinical data for its treatments for skeletal dysplasias, inc

Tone
Positive 72/100
Event
Market update
Published
22 Jun 2026 19:10
Source
Insider Monkey